$10.46
-2.8%Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Acceptable margins but limited operational leverage. Operating expense control is important.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
PRGO โข NYSE
| Perrigo Company plc Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
4.3B | 4.4B | 4.7B | 4.5B | 4.1B | 4.1B | 3.9B | 4.7B | 4.9B | 5.3B | 4.6B | 4.1B | 3.5B | 3.2B | 2.8B | 2.3B | 2B | 1.8B | 1.4B | 1.4B | |
GROSS PROFIT | ||||||||||||||||||||
(2.8B) | (2.8B) | (3B) | (3B) | (2.7B) | (2.6B) | (2.4B) | (2.9B) | (3B) | (3.2B) | (2.9B) | (2.6B) | (2.3B) | (2.1B) | (1.8B) | (1.5B) | (1.4B) | (1.3B) | (1B) | (969.1M) | |
1.5B | 1.5B | 1.7B | 1.5B | 1.4B | 1.5B | 1.4B | 1.8B | 2B | 2.1B | 1.7B | 1.4B | 1.3B | 1.1B | 944.9M | 746M | 596M | 551M | 401.6M | 397.7M | |
OPERATING INCOME | ||||||||||||||||||||
(1.2B) | (1.4B) | (1.5B) | (1.4B) | (1B) | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.4B) | (959.6M) | (827.7M) | (589M) | (517.6M) | (411.3M) | (381.6M) | (333.8M) | (348.4M) | (293.9M) | (277.6M) | |
(526.5M) | (1.1B) | (1.3B) | (1.2B) | (1.1B) | (1.1B) | (1.1B) | (1.1B) | (1.1B) | (1.2B) | (771.8M) | (675.2M) | (473.8M) | (473.8M) | (411.8M) | (299.1M) | (255.8M) | (276.2M) | (227.5M) | (225.3M) | |
(95.4M) | (112.2M) | (122.5M) | (123.1M) | (122M) | (121.7M) | (119.2M) | (218.6M) | (167.7M) | (184M) | (187.8M) | (152.5M) | (115.2M) | (105.8M) | (89.3M) | (82.5M) | (77.9M) | (72.2M) | (66.5M) | (52.3M) | |
343.3M | 112.9M | 151.9M | 78.9M | 410.4M | 265.2M | 174.7M | 236.5M | 598.2M | -2B | 747.6M | 567M | 679.1M | 569.2M | 490.2M | 335.9M | 247.3M | 197.5M | 98.6M | 111.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(162.5M) | (187.8M) | (173.8M) | (156M) | (125M) | (127.7M) | (126.5M) | (129M) | (173.4M) | (218.8M) | (155.7M) | (175.8M) | (103.5M) | (0.0) | (60.7M) | (28.8M) | (27.2M) | (17M) | (16M) | (5.4M) | |
-162.5M | -187.8M | -173.8M | -156M | -125M | -127.7M | -126.5M | -129M | -173.4M | -218.8M | -155.7M | -175.8M | -103.5M | 0.0 | -60.7M | -42.3M | -28.4M | -27.2M | -17.4M | -16M | |
(529.3M) | (205M) | (131.4M) | (43.3M) | -227.6M | -1.1M | (42.6M) | -6.1M | (10.1M) | (0.0) | (0.0) | (0.0) | -900K | (0.0) | -42.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.6B | -193.6M | -160.2M | -218M | -151.7M | -259.3M | -26.7M | 54.1M | -318.1M | -2.8B | -499.6M | -412.2M | -267.8M | -71.4M | -57.2M | -39.6M | -27.3M | -43.5M | -16.9M | -5.4M | |
-1.3B | -80.7M | -8.3M | -139.1M | 258.7M | 5.9M | 148M | 290.6M | 280.1M | -4.8B | 248M | 272.6M | 607.7M | 512M | 450.6M | 308.2M | 203.8M | 180.4M | 89.1M | 105.9M | |
NET INCOME | ||||||||||||||||||||
(104.4M) | (80M) | -3.9M | -8.2M | (389.6M) | -38.3M | -10.7M | (159.6M) | (160.5M) | -835.5M | (120.1M) | (67.3M) | (165.8M) | (119M) | (110M) | (84.1M) | (62.7M) | (44.7M) | (15.3M) | (34.5M) | |
-1.4B | -171.8M | -12.7M | -140.6M | -68.9M | -162.6M | 146.1M | 131M | 119.6M | -4B | 127.9M | 205.3M | 441.9M | 401.6M | 339.2M | 222.5M | 144M | 135.8M | 73.8M | 71.4M |
PRGO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 20, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 20, 2026 | April 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 27, 2025 | 2025 |
Continue your PRGO research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.